首页> 美国卫生研究院文献>Case Reports in Gastroenterology >Acute Liver Failure after Treatment with Rivaroxaban for Aortic Thrombosis Associated with COVID-19 Infection and Methylenetetrahydrofolate Reductase Gene Polymorphism (C677T)
【2h】

Acute Liver Failure after Treatment with Rivaroxaban for Aortic Thrombosis Associated with COVID-19 Infection and Methylenetetrahydrofolate Reductase Gene Polymorphism (C677T)

机译:利伐沙班治疗与 COVID-19 感染相关的主动脉血栓形成和亚甲基四氢叶酸还原酶基因多态性 (C677T) 后急性肝功能衰竭

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Coronavirus disease-2019 (COVID-19) has become associated with prothrombotic state that could lead to severe arterial thrombotic complications. In the case of severe COVID-19 infection, hepatic dysfunction has been observed in more than 50% of patients. In this article, we present a case of aortic thrombosis associated with COVID-19 infection and methylenetetrahydrofolate reductase gene polymorphism (C677T) treated with rivaroxaban resulting in acute liver failure with fatal outcome.
机译:2019 冠状病毒病 (COVID-19) 已与血栓形成前状态有关,这可能导致严重的动脉血栓形成并发症。在严重 COVID-19 感染的情况下,已在超过 50% 的患者中观察到肝功能障碍。在本文中,我们介绍了一例与 COVID-19 感染和亚甲基四氢叶酸还原酶基因多态性 (C677T) 相关的主动脉血栓形成病例,用利伐沙班治疗导致急性肝功能衰竭并导致致命结局。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号